Vered Bisker-Leib, Ph.D., MBA is a member of our board of directors and serves on the audit committee and compensation committee since August 2020. Dr. Bisker-Leib is the Chief Operating Officer of Compass Therapeutics, Inc. where she has been a member of the executive leadership team since November 2017. In this role, she oversees the day-to-day operations of the company, including strategy, finance, business development, legal affairs, research operations, alliance management and communication.  Prior to Compass, Vered was an Executive-In -Residence with Atlas Ventures, where she advised Atlas portfolio companies. Previously, as the Chief Business Officer of Cydan, she founded biotech companies focused on therapies addressing rare diseases, including Imara, (Nasdaq: IMRA) a company developing a therapy for sickle cell disease.  Earlier in her career, Vered was a member of Bristol-Myers Squibb’s (NYSE: BMY) strategic transactions group where she assumed roles of increasing responsibility across five therapeutic areas, most recently as an Executive Director and Global Head of business development for the cardiovascular and metabolic franchises. She led a team responsible for the business development strategy and its execution, culminating in the licensing of pre-clinical and clinical stage programs from Alder, AmbrX, and Portola, and the acquisitions of ZymoGenetics, Amira Pharmaceuticals, and Amylin among others. Vered received a PhD in Chemical Engineering and MBA from the University of Massachusetts, Amherst, where she was a Lois Pope MBA Scholar. She has a B.Sc. in Chemical Engineering from the Israel Institute of Technology, Haifa.  As an Israeli native, Vered completed mandatory service in the Israeli Defense Forces, where she was promoted to the rank of First Lieutenant. We believe that Dr. Bisker-Leib is qualified to serve on our board of directors because of her broad strategic, transaction, financial and operational experience in the industry.